MedTrace Logo

Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.

NCT00040573 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2009-03-31

No results posted yet for this study

Summary

This drug is being developed to treat a type of brain cancer, glioma. This study was designed to determine a safe and well tolerated dose. Patients must have had prior treatment for their glioma and be eligible for removal of their recurring tumor.

Conditions

Interventions

DRUG

131I-TM-601

Sponsors & Collaborators

  • TransMolecular

    lead INDUSTRY

Principal Investigators

  • Diana M Hablitz, MSNCRNP · TransMolecular

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Completion
2003-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00040573 on ClinicalTrials.gov